Reduction of Risk of Secondary Progressive Multiple Sclerosis Within Two Years of Treatment with Cladribine Tablets: An Analysis of the CLARITY Study

Patrick Vermersch, Gavin Giovannoni, Per Soelberg Sørensen, Kottil Rammohan, Stuart Cook, Birgit Keller, Sanjeev Roy